Normunity CEO Rachel Humphrey and founder Lieping Chen

PD-L1 pi­o­neer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tu­mors

In 2015, Lieping Chen — the I/O re­searcher whose ear­ly work es­tab­lished the PD-1/PD-L1 as a can­cer tar­get and the co-founder of Am­plim­mune, bought out by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.